{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041156","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.131269+00:00","generated_at":"2026-06-08T03:47:19.561283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AgeX Q3 net loss $5.4M; $36M debt converted to preferred; going concern raised","bullets":["Net loss of $5.4M ($0.14 diluted EPS) vs $2.4M loss ($0.06) in Q3 2022.","Cash and equivalents only $0.4M at Sept 30; received $4.4M credit line increase from Juvenescence.","Converted $36M of debt into Series A/B preferred stock in July, eliminating that liability.","Signed merger agreement to acquire Serina Therapeutics; G&A surged due to deal costs.","Company discloses substantial doubt about ability to continue as going concern."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041156","json":"https://secwatch.observer/filing/0001493152-23-041156.json","markdown":"https://secwatch.observer/filing/0001493152-23-041156.md","text":"https://secwatch.observer/filing/0001493152-23-041156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223041156/0001493152-23-041156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223041156/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:47:19.561283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fe21e7d448cdde94acf71b21ec79c55e9fe4661","claim":"Serina Therapeutics, Inc. reported quarter and nine months ended September 30, 2023 results: net income $5.4 million, or ($0.14) per share (basic and diluted), EPS ($0.14) per share (basic and diluted).","evidence_excerpt":"AgeX issued a press release announcing its financial results for the quarter and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223041156/0001493152-23-041156-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and nine months ended September 30, 2023"},{"label":"Net income","value":"$5.4 million, or ($0.14) per share (basic and diluted)"},{"label":"EPS","value":"($0.14) per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}